☆ 4.6 Article

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Monique B. Nilsson et al.

Summary: This study identified CD70 as a significantly upregulated cell surface protein in non-small cell lung cancer (NSCLC) patients with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) through epithelial-to-mesenchymal transition (EMT). CD70 promotes cell survival and invasiveness by reactivating signal transduction pathways associated with acquired TKI resistance. Anti-CD70 antibody drug conjugates (ADCs) as well as CD70-targeting chimeric antigen receptor (CAR) T cells and CAR NK cells showed strong activity against EGFR TKI-resistant cells. These findings suggest that CD70 could serve as a therapeutic target for EGFR mutant tumors with acquired TKI resistance.

CANCER CELL (2023)

添加到收藏夹

Article Multidisciplinary Sciences

RHOJ controls EMT-associated resistance to chemotherapy

Maud Debaugnies et al.

Summary: This study reveals that cancer cells undergoing EMT are highly resistant to various anti-cancer therapies. RHOJ, a small GTPase preferentially expressed in EMT cancer cells, controls resistance to therapy by enhancing the response to replicative stress and activating the DNA-damage response. RHOJ interacts with proteins that regulate nuclear actin, and inhibition of actin polymerization sensitizes EMT tumor cells to chemotherapy-induced cell death in a RHOJ-dependent manner.

NATURE (2023)

添加到收藏夹

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Anna Adam-Artigues et al.

Summary: AXL overexpression is identified as an essential mechanism of trastuzumab resistance in HER2-positive breast cancer, and targeting AXL can restore trastuzumab response. AXL may serve as a predictive biomarker for prognosis in HER2-positive breast cancer patients. The study emphasizes the importance of targeting AXL in combination with anti-HER2 drugs to overcome resistance.

SCIENCE ADVANCES (2022)

添加到收藏夹

Article Oncology

Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma

Beiyuan Hu et al.

Summary: Lenvatinib, a first-line treatment for hepatocellular carcinoma (HCC), has limited clinical benefits. This study reveals that HCC cells develop resistance to Lenvatinib by activating the EGFR-STAT3-ABCB1 pathway. Combined treatment with erlotinib, an EGFR inhibitor, may overcome acquired resistance and improve the clinical benefit of Lenvatinib.

CANCER RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization

Tugce Batur et al.

Summary: The study reveals that AXL is highly expressed in advanced hepatocellular carcinoma and is closely associated with a mesenchymal phenotype. By using gene knockout and pharmacological inhibition, it was found that loss of AXL leads to drastic phenotypic changes in HCC cells, resulting in loss of tumorigenicity in vivo.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Review Oncology

Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors

Viola Hedrich et al.

Summary: The receptor tyrosine kinases Tyro3, Axl, and MerTK of the TAM family play a significant role in hepatocellular carcinoma progression. They exert their impact on cancer biology by modulating epithelial cell plasticity and promoting metastatic traits of neoplastic hepatocytes. By activating TAM receptors, they influence anti-inflammatory responses, vessel integrity, and resistance to chemotherapy.

CANCERS (2021)

添加到收藏夹

Review Oncology

The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications

Martha Wium et al.

Summary: Axl is an oncogene that promotes cancer development and resistance to therapy, with inhibitors currently in clinical trials. Understanding the role of Axl in drug resistance can lead to improved cancer therapeutic strategies.

CANCERS (2021)

添加到收藏夹

Review Oncology

Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer

Fatema Tuz Zahra et al.

Summary: Anti-angiogenic therapies targeting VEGF signaling have shown temporary benefits in cancer treatment, with resistance often developing due to the upregulation of other growth factors like bFGF. Recent efforts have focused on developing multi-target anti-angiogenic drugs to overcome resistance mechanisms and improve outcomes in clinical practice.

CANCERS (2021)

添加到收藏夹

Article Oncology

Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor

Aldo Prawira et al.

Summary: In this study, the upregulation of the ErbB family by EZH2 was found to contribute to infigratinib resistance in hepatocellular carcinoma. Combination therapy with infigratinib and varlitinib effectively overcame resistance and prolonged antitumor response without additional toxicity, suggesting the need for further clinical investigation.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy

Masashi Mikubo et al.

Summary: A minor population of cancer cells can evade cell death from chemotherapy and targeted therapy by entering a reversible slow proliferation state known as the drug tolerant persister (DTP) state. Understanding the biology of DTP cells and developing therapeutic strategies targeting this mechanism can have significant clinical implications in overcoming cancer persistence. Emerging evidence suggests that DTP cells adapt to new environments through epigenomic modification, transcriptomic regulation, flexible energy metabolism, and interactions with the tumor microenvironment.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

EGFR activation limits the response of liver cancer to lenvatinib

Haojie Jin et al.

Summary: Inhibition of EGFR is synthetically lethal with lenvatinib in liver cancer, and the combination of lenvatinib with the EGFR inhibitor gefitinib shows potent anti-proliferative effects both in vitro and in vivo. This combination therapy could be a promising strategy for HCC patients with high levels of EGFR, providing meaningful clinical responses.

NATURE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Experience with regorafenib in the treatment of hepatocellular carcinoma

Alessandro Granito et al.

Summary: Regorafenib, structurally similar to sorafenib, shows significant survival advantage in unresectable hepatocellular carcinoma (HCC) patients who failed first-line treatment, by targeting angiogenic and tumor growth-promoting pathways, inhibiting tumor neo-angiogenesis and proliferation, and modulating the tumor microenvironment. It is being explored for use in combination therapy with immune checkpoint blockade and for extended use in patient categories beyond registrative studies.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma

Carmen Oi Ning Leung et al.

HEPATOLOGY (2020)

添加到收藏夹

Review Surgery

Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review

Thibaut D'Izarny-Gargas et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2020)

添加到收藏夹

Article Oncology

Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma

Haijing Deng et al.

LIVER CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma

Martin Golkowski et al.

CELL SYSTEMS (2020)

添加到收藏夹

Review Oncology

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma

Jose J. G. Marin et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

David J. Pinato et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway

Jichuang Wang et al.

CANCER LETTERS (2019)

添加到收藏夹

Article Oncology

KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program

Yanmin Xu et al.

CANCER LETTERS (2019)

添加到收藏夹

Article Oncology

A Pharmacogenomic Landscape in Human Liver Cancers

Zhixin Qiu et al.

CANCER CELL (2019)

添加到收藏夹

Review Cell Biology

New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer

Anushka Dongre et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Medicine, General & Internal

TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma

Wenliang Tan et al.

EBIOMEDICINE (2019)

添加到收藏夹

Article Oncology

Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells

Irene Scharf et al.

ONCOLOGY LETTERS (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer

Shang-Gin Wu et al.

MOLECULAR CANCER (2018)

添加到收藏夹

Article Cell Biology

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression

Marie-Anne Goyette et al.

CELL REPORTS (2018)

添加到收藏夹

Review Oncology

Molecular therapies and precision medicine for hepatocellular carcinoma

Josep M. Llovet et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Victoria Tovar et al.

GUT (2017)

添加到收藏夹

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

添加到收藏夹

Article Biochemical Research Methods

Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay

Mirko Dengler et al.

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2016)

添加到收藏夹

Article Cell Biology

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

P-F Zhang et al.

CELL DEATH & DISEASE (2016)

添加到收藏夹

Article Oncology

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

Miles A. Miller et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Axl Activates Autocrine Transforming Growth Factor-β Signaling in Hepatocellular Carcinoma

Patrick Reichl et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Oncology

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Carlos L. Arteaga et al.

CANCER CELL (2014)

添加到收藏夹

Article Oncology

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

Catherine Wilson et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

Mihalis S. Kariolis et al.

NATURE CHEMICAL BIOLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

Erinn B. Rankin et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Michael I. Love et al.

GENOME BIOLOGY (2014)

添加到收藏夹

Article Biochemical Research Methods

STAR: ultrafast universal RNA-seq aligner

Alexander Dobin et al.

BIOINFORMATICS (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao et al.

SCIENCE SIGNALING (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition

Michaela Petz et al.

NUCLEIC ACIDS RESEARCH (2012)

添加到收藏夹

Article Oncology

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Franziska van Zijl et al.

MOLECULAR CANCER THERAPEUTICS (2011)

添加到收藏夹

Article Oncology

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

Agda K. Lucio-Eterovic et al.

CLINICAL CANCER RESEARCH (2009)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

A Subramanian et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.